TDAC NASDAQ
Translational Development Acquisition Corp.
1W: +0.1%
1M: +0.2%
3M: +0.5%
YTD: +2.4%
1Y: +3.9%
$10.84
+0.10 (+0.93%)
Weekly Expected Move ±0.3%
$11
$11
$11
$11
$11
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider+$0.6M
Congress—
ETF Holdings—
Key Statistics
Market Cap$267.0M
52W Range10.318-10.9
Volume306,565
Avg Volume103,250
Beta0.02
Dividend—
Analyst Ratings
Company Info
CEOMichael Hoffman
Employees2
SectorFinancial Services
IndustryShell Companies
IPO Date2025-02-20
52 E. 83rd Street
New York City, NY 10006
US
New York City, NY 10006
US
16462297549
About Translational Development Acquisition Corp.
Translational Development Acquisition Corp., founded in 2022 and headquartered in New York, New York, currently conducts no significant business operations. Its primary goal is to complete a business combination, such as a merger, amalgamation, share exchange, asset acquisition, share purchase, or reorganization, with one or more companies.
Latest News
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Translational Development Acquisition Corp. (NASDAQ: TDAC)
ProLogium, a Next Generation Solid-State Battery Developer with 10+ Years of Proven Commercialization, to List on the Nasdaq through a Merger with Translational Development Acquisition Corp.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hoffman Michael B | P-Purchase | 53,395 | $11.50 | 2026-05-27 |
| Jarratt Christopher | 0 | — | 2024-12-20 | |
| Keith Curtis T | 0 | — | 2024-12-20 | |
| TDAC Partners LLC | 4,657,500 | — | 2024-12-20 | |
| Reddy E Premkumar | 0 | — | 2024-12-20 |